公开(公告)号：WO2023087009A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079843

申请日：2022-11-14

申请人： SQZ BIOTECHNOLOGIES COMPANY

发明人： MALONEY, Michael Finnan ,  OZAY, Emrah Ilker ,  LOUGHHEAD, Scott McNabb ,  SILVER, Rebecca Jean ,  BRATE, Ashley ,  SILVA, Murillo ,  GILBERT, Jonathan B. ,  BRIDGEN, Devin ,  THALHOFER, Colin Joseph

IPC分类号： C12N5/0783 ,  C12M1/42 ,  C12N15/87 ,  A61P35/00 ,  C07K14/54 ,  A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  C12N5/0781 ,  A61K35/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/705

摘要： The present application provides TILs comprising agents that enhance activity and/or proliferative capacity of the TILs, methods of manufacturing such TILs, and methods of using such modified TILs for enhancing an immune response.

公开(公告)号：WO2023067582A1

公开(公告)日：2023-04-27

申请号：PCT/IB2022/060192

申请日：2022-10-24

申请人： MAZUMDAR SHAW MEDICAL FOUNDATION

发明人： DAS, Manjula ,  SURESH, Amritha ,  KURIAKOSE, Moni ,  PILLAI, Vijay ,  GANGADHARA, Charitha ,  DWIVEDI, Nehanjali ,  P K, Smitha ,  SHUKLA, Nidhi ,  KULSUM, Safeena ,  SIDDAPPA, Gangotri ,  DHAR, Sujan

IPC分类号： A61K35/00 ,  A61P35/00 ,  G01N33/00

摘要： The present disclosure relates to a tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression. More particularly, invention focuses on a method for obtaining a tumor microenvironment platform comprising oral carcinoma for predicting chemoresistance and dysplastic progression primary cell lines derived from oral cancer patients, their characterization and validation as a model in early carcinogenesis and chemoresistance. Furthermore, invention deals with autologous pair of cancer cell line and development of Cancer Associated Fibroblast (CAF) cell lines from patients. In further embodiment, invention deals with development of spontaneously transformed cell lines from patients with oral cancer. In addition, the invention also provides kits that are useful for the practice of the methods of the invention.

公开(公告)号：WO2023062577A1

公开(公告)日：2023-04-20

申请号：PCT/IB2022/059819

申请日：2022-10-13

申请人： ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA

发明人： VITALI, Beatrice ,  PAROLIN, Carola Eleonora ,  GIORDANI, Barbara ,  LUPPI, Barbara ,  ABRUZZO, Angela ,  MARANGONI, Antonella ,  FOSCHI, Claudio

IPC分类号： A23L33/135 ,  A61K35/747 ,  A61K35/00

摘要： The Limosilactobacillus vaginalis BC17 strain, deposited with number DSM 34059, is usable as an agent for promoting a proliferation of intestinal bifidobacteria in a human subject. A method for promoting the proliferation of intestinal bifidobacteria in a human subject provides for administering to the human subject the Limosilactobacillus vaginalis BC17 strain deposited with number DSM 34059. The strain can be incorporated into a liquid or solid composition that can be administered orally or buccally and the human subject can be a neonate or a suckling. The strain can also be used to prepare compositions that are applicable to the skin of the nipples of a breast-feeding woman.

公开(公告)号：WO2023057390A1

公开(公告)日：2023-04-13

申请号：PCT/EP2022/077471

申请日：2022-10-03

申请人： URGO RECHERCHE INNOVATION ET DEVELOPPEMENT

发明人： BERTRAND, Eugénie ,  GENTILHOMME, Marilyn ,  VIGNEAU, Aurore

IPC分类号： A61K35/644 ,  A61K9/00 ,  A61K36/185 ,  A61K36/31 ,  A61P1/00 ,  A61P29/00 ,  A61K9/20 ,  A61K35/00 ,  A61K9/0056 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2063 ,  A61K9/2068

摘要： La présente invention a pour objet un produit de combinaison comprenant à titre de substances actives, au moins du miel, de la propolis, de l'erysimum et de la mauve pour aider à soulager les maux de gorges. L'invention concerne enfin l'utilisation d'un produit de combinaison tel que précédemment défini pour le traitement des maux de gorges.

公开(公告)号：WO2023047404A1

公开(公告)日：2023-03-30

申请号：PCT/IL2022/051020

申请日：2022-09-25

申请人： MYBIOTICS PHARMA LTD.

发明人： DABOUSH, David ,  WEISSMAN, Lior ,  KILOVATY, Itay ,  LEV, Igor ,  SHTRIKMAN, Alon ,  ELI, Dorit

IPC分类号： C12N11/04 ,  C12P39/00 ,  A23K10/18 ,  C12N1/20 ,  A61K35/74 ,  A61K35/00 ,  A61P1/00

摘要： The present invention, in some embodiments, is directed to a method for producing a composition including a co-culture comprising a plurality of bacteria having a high similarity % to an origin sample and bacterial load.

公开(公告)号：WO2023041809A1

公开(公告)日：2023-03-23

申请号：PCT/EP2022/076135

申请日：2022-09-20

申请人： PULMOBIOTICS, S.L. ,  FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA ,  INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS

发明人： MAZZOLINI, Rocco ,  LLUCH SENAR, María ,  RIBEIRO DOS SANTOS, Claudio Joao ,  SERRANO PUBUL, Luis

IPC分类号： C12N15/74 ,  A61L2/00 ,  A61P31/04 ,  C12N1/36 ,  A61K35/00

摘要： The present invention concerns genetically modified Mycoplasma bacteria that express gene products having an anti-biofilm activity against a biofilm formed by multiple bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. Further intended are pharmaceutical compositions comprising genetically modified Mycoplasma bacteria and their use as a medicament.

公开(公告)号：WO2023288041A1

公开(公告)日：2023-01-19

申请号：PCT/US2022/037251

申请日：2022-07-15

申请人： PURDUE RESEARCH FOUNDATION ,  RUSH UNIVERSITY MEDICAL CENTER

发明人： KESHAVARZIAN, Ali ,  HAMAKER, Bruce, R. ,  MORO CANTU JUNGLES, Thaisa

IPC分类号： A61K31/00 ,  A61K31/70 ,  A61K31/715 ,  A61K31/733 ,  A61K35/00

摘要： A composition comprising (i) a resistant starch, (ii) resistant dextrin/ maltodextrin, a resistant non-starch α-linked glucan, or both, (iii) a cereal bran, which is optionally stabilized, and (iv) inulin, a fructooligosaccharide, or both; an ingestible formulation comprising the composition; and a method of improving gastrointestinal health in a human with a condition, disease, or disorder, which method comprises administering to the human the composition or the ingestible formulation.

公开(公告)号：WO2023283320A2

公开(公告)日：2023-01-12

申请号：PCT/US2022/036336

申请日：2022-07-07

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： MANIRUZZAMAN, Mohammed ,  WANG, Jiawei ,  AGHDA, Niloofar Heshmati ,  ZHANG, Yu

IPC分类号： B05B1/02 ,  A61K9/107 ,  B29C64/10 ,  B01F23/40 ,  A61K9/16 ,  B01F23/4146 ,  A61K35/00 ,  A61K9/1647 ,  A61K9/1652 ,  A61K9/1694 ,  B29C64/106 ,  B33Y10/00 ,  B33Y80/00

摘要： Described are techniques, systems, and methods include those employing pneumatic, pressure assisted, extrusion-based 3D printing and emulsion evaporation, emulsion diffusion, nanoprecipitation, desolvation, gelation, spray-based atomization, etc. for fabricating loaded microparticles or nanoparticles that encapsulate an active pharmaceutical ingredient or live cells into a biocompatible polymer or pharmaceutical excipients. The techniques provide for encapsulation of a variety of substances including proteins, plasmid DNA, lipophilic pharmaceutical compositions, hydrophilic pharmaceutical compositions, live cells, and/or cellular components into polymeric microparticles or nanoparticles. The particles loaded with active pharmaceutical ingredients can be used for the treatment of different diseases or conditions. The particles loaded with live cells can be used for disease treatment, but can also be used for securely storing the live cells in a stable condition for transport and later use in inoculating fermentation systems, for example, to generate recombinant proteins.

公开(公告)号：WO2022271798A1

公开(公告)日：2022-12-29

申请号：PCT/US2022/034482

申请日：2022-06-22

申请人： BRANDEIS UNIVERSITY

发明人： LIU, Shuang ,  LU, Shijiang ,  XU, Bing

IPC分类号： A61K47/42 ,  C07K7/06 ,  A61K9/00 ,  A61K35/00

摘要： An isolated peptide having the structure: where — NH — Q — C(O) — is an α-helical amino acid sequence that includes at least 4 and up to 30 amino acid residues, Z1 is a moiety including an aromatic group or a fluorophore, Z2 includes a phosphorylated amino acid residue, or the dephosphorylated amino acid residue. These peptides, in dephosphorylated form, are capable of self-assembly in the form of a nanoribbon, nanofiber, or a combination thereof. Such peptides are capable of causing cell death of cells that overexpress alkaline phosphatases, which includes cancer cells and induced pluripotent stem cells (iPSCs), and therefore the peptides of the invention can be used ex vivo to selectively cause cell death of cancer cells or iPSCs, or in vivo to cause cancer cell death.

公开(公告)号：WO2022224273A1

公开(公告)日：2022-10-27

申请号：PCT/IN2022/050373

申请日：2022-04-19

申请人： SRIKANT, Dr Niriee

发明人： SRIKANT, Dr Niriee

IPC分类号： A61K35/00 ,  A23L33/135

摘要： The present invention relates to a novel psychobiotic composition comprising combination of twelve strains of probiotics selected from following genus Saccharomyces, Bifidobacterium, Lactobacillus and Streptococcus, wherein the composition is effective in restoring gut-brain axis. Further, the invention discloses a novel psychobiotic composition to treat conditions associated with autism or autism spectrum disorders, wherein the composition comprising combination of twelve specific strains of probiotics. The disclosed psychobiotic composition of the invention restores gut health and establishes the gut-brain signaling and there by reduces gut dysbiosis and neuronal inflammation.